O	0	3	The
O	4	10	Effect
O	11	13	of
B-intervention	14	25	Abemaciclib
I-intervention	26	30	Plus
I-intervention	31	42	Fulvestrant
O	43	45	on
O	46	53	Overall
O	54	62	Survival
O	63	65	in
O	66	73	Hormone
O	74	82	Receptor
O	82	83	-
O	83	91	Positive
O	91	92	,
O	93	98	ERBB2
O	98	99	-
O	99	107	Negative
O	108	114	Breast
O	115	121	Cancer
O	122	126	That
O	127	137	Progressed
O	138	140	on
O	141	150	Endocrine
O	151	158	Therapy
O	158	159	-
O	159	166	MONARCH
O	167	168	2
O	168	169	:
O	170	171	A
O	172	182	Randomized
O	183	191	Clinical
O	192	197	Trial
O	197	198	.

O	199	212	Statistically
O	213	224	significant
O	225	232	overall
O	233	241	survival
O	242	243	(
O	243	245	OS
O	245	246	)
O	247	255	benefits
O	256	258	of
O	259	263	CDK4
O	264	267	and
O	268	272	CDK6
O	273	283	inhibitors
O	284	286	in
O	287	298	combination
O	299	303	with
O	304	315	fulvestrant
O	316	319	for
O	320	327	hormone
O	328	336	receptor
O	337	338	(
O	338	340	HR
O	340	341	)
O	341	342	-
O	342	350	positive
O	350	351	,
O	352	357	ERBB2
O	358	359	(
O	359	367	formerly
O	368	372	HER2
O	372	373	)
O	373	374	-
O	374	382	negative
O	383	391	advanced
O	392	398	breast
O	399	405	cancer
O	406	407	(
O	407	410	ABC
O	410	411	)
O	412	414	in
O	415	423	patients
O	424	434	regardless
O	435	437	of
O	438	448	menopausal
O	449	455	status
O	456	461	after
O	462	467	prior
O	468	477	endocrine
O	478	485	therapy
O	486	487	(
O	487	489	ET
O	489	490	)
O	491	494	has
O	495	498	not
O	499	502	yet
O	503	507	been
O	508	520	demonstrated
O	520	521	.

O	522	524	To
O	525	532	compare
O	533	536	the
O	537	543	effect
O	544	546	of
O	547	558	abemaciclib
O	559	563	plus
O	564	575	fulvestrant
O	576	578	vs
O	579	586	placebo
O	587	591	plus
O	592	603	fulvestrant
O	604	606	on
O	607	609	OS
O	610	612	at
O	613	616	the
O	617	629	prespecified
O	630	637	interim
O	638	640	of
O	641	648	MONARCH
O	649	650	2
O	651	652	(
O	652	655	338
O	656	662	events
O	662	663	)
O	664	666	in
O	667	675	patients
O	676	680	with
O	681	683	HR
O	683	684	-
O	684	692	positive
O	692	693	,
O	694	699	ERBB2
O	699	700	-
O	700	708	negative
O	709	717	advanced
O	718	724	breast
O	725	731	cancer
O	732	736	that
O	737	747	progressed
O	748	754	during
O	755	760	prior
O	761	763	ET
O	763	764	.

O	765	772	MONARCH
O	773	774	2
O	775	778	was
O	779	780	a
O	781	787	global
O	787	788	,
O	789	799	randomized
O	799	800	,
O	801	808	placebo
O	808	809	-
O	809	819	controlled
O	819	820	,
O	821	827	double
O	827	828	-
O	828	833	blind
O	834	839	phase
O	840	841	3
O	842	847	trial
O	848	850	of
O	851	862	abemaciclib
O	863	867	plus
O	868	879	fulvestrant
O	880	882	vs
O	883	890	placebo
O	891	895	plus
O	896	907	fulvestrant
O	908	911	for
O	912	921	treatment
O	922	924	of
O	925	938	premenopausal
O	939	941	or
O	942	956	perimenopausal
O	957	962	women
O	963	964	(
O	964	968	with
O	969	976	ovarian
O	977	988	suppression
O	988	989	)
O	990	993	and
O	994	1008	postmenopausal
O	1009	1014	women
O	1015	1019	with
O	1020	1022	HR
O	1022	1023	-
O	1023	1031	positive
O	1031	1032	,
O	1033	1038	ERBB2
O	1038	1039	-
O	1039	1047	negative
O	1048	1051	ABC
O	1052	1056	that
O	1057	1067	progressed
O	1068	1074	during
O	1075	1077	ET
O	1077	1078	.

O	1079	1087	Patients
O	1088	1092	were
O	1093	1101	enrolled
O	1102	1109	between
O	1110	1116	August
O	1117	1118	7
O	1118	1119	,
O	1120	1124	2014
O	1124	1125	,
O	1126	1129	and
O	1130	1138	December
O	1139	1141	29
O	1141	1142	,
O	1143	1147	2015
O	1147	1148	.

O	1149	1157	Analyses
O	1158	1161	for
O	1162	1166	this
O	1167	1173	report
O	1174	1178	were
O	1179	1188	conducted
O	1189	1191	at
O	1192	1195	the
O	1196	1200	time
O	1201	1203	of
O	1204	1212	database
O	1213	1217	lock
O	1218	1220	on
O	1221	1225	June
O	1226	1228	20
O	1228	1229	,
O	1230	1234	2019
O	1234	1235	.

O	1236	1244	Patients
O	1245	1249	were
O	1250	1260	randomized
O	1261	1262	2
O	1262	1263	:
O	1263	1264	1
O	1265	1267	to
O	1268	1275	receive
O	1276	1287	abemaciclib
O	1288	1290	or
O	1291	1298	placebo
O	1298	1299	,
O	1300	1303	150
O	1304	1306	mg
O	1306	1307	,
O	1308	1313	every
O	1314	1316	12
O	1317	1322	hours
O	1323	1325	on
O	1326	1327	a
O	1328	1338	continuous
O	1339	1347	schedule
O	1348	1352	plus
O	1353	1364	fulvestrant
O	1364	1365	,
O	1366	1369	500
O	1370	1372	mg
O	1372	1373	,
O	1374	1377	per
O	1378	1383	label
O	1383	1384	.

O	1385	1398	Randomization
O	1399	1402	was
O	1403	1413	stratified
O	1414	1419	based
O	1420	1422	on
O	1423	1427	site
O	1428	1430	of
O	1431	1441	metastasis
O	1442	1443	(
O	1443	1451	visceral
O	1451	1452	,
O	1453	1457	bone
O	1458	1462	only
O	1462	1463	,
O	1464	1466	or
O	1467	1472	other
O	1472	1473	)
O	1474	1477	and
O	1478	1488	resistance
O	1489	1491	to
O	1492	1497	prior
O	1498	1500	ET
O	1501	1502	(
O	1502	1509	primary
O	1510	1512	vs
O	1513	1522	secondary
O	1522	1523	)
O	1523	1524	.

O	1525	1528	The
O	1529	1536	primary
O	1537	1540	end
O	1541	1546	point
O	1547	1550	was
O	1551	1563	investigator
O	1563	1564	-
O	1564	1572	assessed
B-outcome-Measure	1573	1584	progression
I-outcome-Measure	1584	1585	-
I-outcome-Measure	1585	1589	free
I-outcome-Measure	1590	1598	survival
O	1598	1599	.

B-outcome-Measure	1600	1607	Overall
I-outcome-Measure	1608	1616	survival
O	1617	1620	was
O	1621	1622	a
O	1623	1628	gated
O	1629	1632	key
O	1633	1642	secondary
O	1643	1646	end
O	1647	1652	point
O	1652	1653	.

O	1654	1657	The
O	1658	1666	boundary
O	1667	1668	P
O	1669	1674	value
O	1675	1678	for
O	1679	1682	the
O	1683	1690	interim
O	1691	1699	analysis
O	1700	1703	was
O	1704	1705	.
O	1705	1707	02
O	1707	1708	.

O	1709	1711	Of
B-total-participants	1712	1715	669
O	1716	1721	women
O	1722	1730	enrolled
O	1730	1731	,
B-intervention-participants	1732	1735	446
O	1736	1737	(
O	1737	1743	median
O	1744	1745	[
O	1745	1750	range
O	1750	1751	]
O	1752	1755	age
O	1755	1756	,
O	1757	1759	59
O	1760	1761	[
O	1761	1763	32
O	1763	1764	-
O	1764	1766	91
O	1766	1767	]
O	1768	1773	years
O	1773	1774	)
O	1775	1779	were
O	1780	1790	randomized
O	1791	1793	to
O	1794	1797	the
O	1798	1809	abemaciclib
O	1810	1814	plus
O	1815	1826	fulvestrant
O	1827	1830	arm
O	1831	1834	and
B-control-participants	1835	1838	223
O	1839	1840	(
O	1840	1846	median
O	1847	1848	[
O	1848	1853	range
O	1853	1854	]
O	1855	1858	age
O	1858	1859	,
O	1860	1862	62
O	1863	1864	[
O	1864	1866	32
O	1866	1867	-
O	1867	1869	87
O	1869	1870	]
O	1871	1876	years
O	1876	1877	)
O	1878	1882	were
O	1883	1893	randomized
O	1894	1896	to
O	1897	1900	the
B-control	1901	1908	placebo
I-control	1909	1913	plus
I-control	1914	1925	fulvestrant
O	1926	1929	arm
O	1929	1930	.

O	1931	1933	At
O	1934	1937	the
O	1938	1950	prespecified
O	1951	1958	interim
O	1958	1959	,
O	1960	1963	338
B-outcome	1964	1970	deaths
O	1971	1972	(
O	1972	1974	77
O	1974	1975	%
O	1976	1978	of
O	1979	1982	the
O	1983	1990	planned
O	1991	1994	441
O	1995	1997	at
O	1998	2001	the
O	2002	2007	final
O	2008	2016	analysis
O	2016	2017	)
O	2018	2022	were
O	2023	2031	observed
O	2032	2034	in
O	2035	2038	the
O	2039	2045	intent
O	2045	2046	-
O	2046	2048	to
O	2048	2049	-
O	2049	2054	treat
O	2055	2065	population
O	2065	2066	,
O	2067	2071	with
O	2072	2073	a
B-outcome	2074	2080	median
I-outcome	2081	2083	OS
O	2084	2086	of
B-iv-cont-median	2087	2089	46
I-iv-cont-median	2089	2090	.
I-iv-cont-median	2090	2091	7
I-iv-cont-median	2092	2098	months
O	2099	2102	for
O	2103	2114	abemaciclib
O	2115	2119	plus
O	2120	2131	fulvestrant
O	2132	2135	and
B-cv-cont-median	2136	2138	37
I-cv-cont-median	2138	2139	.
I-cv-cont-median	2139	2140	3
I-cv-cont-median	2141	2147	months
O	2148	2151	for
O	2152	2159	placebo
O	2160	2164	plus
O	2165	2176	fulvestrant
O	2177	2178	(
O	2178	2184	hazard
O	2185	2190	ratio
O	2191	2192	[
O	2192	2194	HR
O	2194	2195	]
O	2195	2196	,
O	2197	2198	0
O	2198	2199	.
O	2199	2202	757
O	2202	2203	;
O	2204	2206	95
O	2206	2207	%
O	2208	2210	CI
O	2210	2211	,
O	2212	2213	0
O	2213	2214	.
O	2214	2217	606
O	2217	2218	-
O	2218	2219	0
O	2219	2220	.
O	2220	2223	945
O	2223	2224	;
O	2225	2226	P
O	2227	2228	=
O	2229	2230	.
O	2230	2232	01
O	2232	2233	)
O	2233	2234	.

O	2235	2246	Improvement
O	2247	2249	in
O	2250	2252	OS
O	2253	2256	was
O	2257	2267	consistent
O	2268	2274	across
O	2275	2278	all
O	2279	2293	stratification
O	2294	2301	factors
O	2301	2302	.

O	2303	2308	Among
O	2309	2323	stratification
O	2324	2331	factors
O	2331	2332	,
B-outcome	2333	2337	more
I-outcome	2338	2348	pronounced
I-outcome	2349	2356	effects
O	2357	2361	were
O	2362	2370	observed
O	2371	2373	in
B-outcome	2374	2382	patients
I-outcome	2383	2387	with
I-outcome	2388	2396	visceral
I-outcome	2397	2404	disease
O	2405	2406	(
O	2406	2408	HR
O	2408	2409	,
O	2410	2411	0
O	2411	2412	.
O	2412	2415	675
O	2415	2416	;
O	2417	2419	95
O	2419	2420	%
O	2421	2423	CI
O	2423	2424	,
O	2425	2426	0
O	2426	2427	.
O	2427	2430	511
O	2430	2431	-
O	2431	2432	0
O	2432	2433	.
O	2433	2436	891
O	2436	2437	)
O	2438	2441	and
B-outcome	2442	2449	primary
I-outcome	2450	2460	resistance
I-outcome	2461	2463	to
I-outcome	2464	2469	prior
I-outcome	2470	2472	ET
O	2473	2474	(
O	2474	2476	HR
O	2476	2477	,
O	2478	2479	0
O	2479	2480	.
O	2480	2483	686
O	2483	2484	;
O	2485	2487	95
O	2487	2488	%
O	2489	2491	CI
O	2491	2492	,
O	2493	2494	0
O	2494	2495	.
O	2495	2498	451
O	2498	2499	-
O	2499	2500	1
O	2500	2501	.
O	2501	2504	043
O	2504	2505	)
O	2505	2506	.

B-outcome	2507	2511	Time
I-outcome	2512	2514	to
I-outcome	2515	2521	second
I-outcome	2522	2529	disease
I-outcome	2530	2541	progression
O	2542	2543	(
O	2543	2549	median
O	2549	2550	,
B-iv-cont-median	2551	2553	23
I-iv-cont-median	2553	2554	.
I-iv-cont-median	2554	2555	1
I-iv-cont-median	2556	2562	months
O	2563	2565	vs
B-cv-cont-median	2566	2568	20
I-cv-cont-median	2568	2569	.
I-cv-cont-median	2569	2570	6
I-cv-cont-median	2571	2577	months
O	2577	2578	)
O	2578	2579	,
B-outcome	2580	2584	time
I-outcome	2585	2587	to
I-outcome	2588	2600	chemotherapy
O	2601	2602	(
O	2602	2608	median
O	2608	2609	,
B-iv-cont-median	2610	2612	50
I-iv-cont-median	2612	2613	.
I-iv-cont-median	2613	2614	2
I-iv-cont-median	2615	2621	months
O	2622	2624	vs
B-cv-cont-median	2625	2627	22
I-cv-cont-median	2627	2628	.
I-cv-cont-median	2628	2629	1
I-cv-cont-median	2630	2636	months
O	2636	2637	)
O	2637	2638	,
O	2639	2642	and
B-outcome	2643	2655	chemotherapy
I-outcome	2655	2656	-
I-outcome	2656	2660	free
I-outcome	2661	2669	survival
O	2670	2671	(
O	2671	2677	median
O	2677	2678	,
B-iv-cont-median	2679	2681	25
I-iv-cont-median	2681	2682	.
I-iv-cont-median	2682	2683	5
I-iv-cont-median	2684	2690	months
O	2691	2693	vs
B-cv-cont-median	2694	2696	18
I-cv-cont-median	2696	2697	.
I-cv-cont-median	2697	2698	2
I-cv-cont-median	2699	2705	months
O	2705	2706	)
O	2707	2711	were
O	2712	2716	also
O	2717	2730	statistically
O	2731	2744	significantly
O	2745	2753	improved
O	2754	2756	in
O	2757	2760	the
O	2761	2772	abemaciclib
O	2773	2776	arm
O	2777	2779	vs
O	2780	2787	placebo
O	2788	2791	arm
O	2791	2792	.

O	2793	2795	No
O	2796	2799	new
B-outcome	2800	2806	safety
I-outcome	2807	2814	signals
O	2815	2819	were
O	2820	2828	observed
O	2829	2832	for
O	2833	2844	abemaciclib
O	2844	2845	.

O	2846	2855	Treatment
O	2856	2860	with
O	2861	2872	abemaciclib
O	2873	2877	plus
O	2878	2889	fulvestrant
O	2890	2898	resulted
O	2899	2901	in
O	2902	2903	a
O	2904	2917	statistically
O	2918	2929	significant
O	2930	2933	and
O	2934	2944	clinically
O	2945	2955	meaningful
B-outcome	2956	2962	median
I-outcome	2963	2965	OS
O	2966	2977	improvement
O	2978	2980	of
O	2981	2982	9
O	2982	2983	.
O	2983	2984	4
O	2985	2991	months
O	2992	2995	for
O	2996	3004	patients
O	3005	3009	with
O	3010	3012	HR
O	3012	3013	-
O	3013	3021	positive
O	3021	3022	,
O	3023	3028	ERBB2
O	3028	3029	-
O	3029	3037	negative
O	3038	3041	ABC
O	3042	3045	who
O	3046	3056	progressed
O	3057	3062	after
O	3063	3068	prior
O	3069	3071	ET
O	3072	3082	regardless
O	3083	3085	of
O	3086	3096	menopausal
O	3097	3103	status
O	3103	3104	.

O	3105	3116	Abemaciclib
O	3117	3130	substantially
O	3131	3138	delayed
O	3139	3142	the
O	3143	3150	receipt
O	3151	3153	of
O	3154	3164	subsequent
O	3165	3177	chemotherapy
O	3177	3178	.

O	3179	3193	ClinicalTrials
O	3193	3194	.
O	3195	3198	gov
O	3199	3209	identifier
O	3209	3210	:
O	3211	3222	NCT02107703
O	3222	3223	.
